Oppenheimer downgrades AtriCure on new competition from Edwards

Oppenheimer downgraded AtriCure (ATRC) to Perform from Outperform without a price target following the Q4 report. Last week, Edwards Lifesciences (EW) announced it was pursuing new left atrial appendage closure products, expected later in 2026, the analyst tells investors in a research note. The firm believes AtriCure is facing a long-term “secular decline. The company’s LeAAPS study might not be enough to prevent Edwards from capitalizing on open ablation left atrial appendage closure given its surgical franchise, the firm contends.